BMRA — Fiscal Q1 2027 (Quarter Ended Aug. 31, 2026) Financial Report Analysis

Biomerica, a small Irvine, California maker of diagnostic test kits, sold $1.27 million of products and services in its fiscal first quarter (the three months ended August 31, 2026), 8% less than a year earlier. The bigger problem was profitability on those sales: gross margin, the share of sales left after the direct cost of making the product, fell to 8.1% from 30.7%. The company lost $1.23 million, against a $2,000 profit a year ago. That year-ago "profit" existed only because of a one-time $1.1 million payroll-tax refund from the IRS, so the real change is smaller than the headline suggests, but the underlying business still lost more money than it did a year ago. A $2.23 million share sale in late August more than doubled cash to $2.73 million. The filing still says that cash is not enough to fund the next twelve months, and it repeats the "substantial doubt" going-concern warning.

At a glance

• Gross margin: 8.1%, down from 30.7%. Of every $100 of sales, only about $8 was left after production costs, before paying any salespeople, administrators or researchers. That's the same 8.1% the company ran for the whole of fiscal 2026, so last year's weak margin wasn't a one-off.
• Net loss: $1.23 million, or $0.37 a share. Strip the $1.1 million IRS refund out of last year's quarter and the comparable loss was about $1.10 million, so the business lost roughly $130,000 more this year.
• Cash: $2.73 million, after raising $2.23 million. Operations used $0.80 million of cash this quarter. At that pace the cash lasts roughly three more quarters, which is why management says it needs more funding.

The numbers

Operating margin is the loss (or profit) from running the business, before interest and tax, as a share of sales. At -97%, Biomerica spent almost two dollars for every dollar of sales it brought in.

Where sales went

The company sells mainly through four channels. Here is how each one moved, according to the filing's revenue breakdown:

• Clinical lab products fell 24% to $775,000. These are test kits sold to hospital and commercial labs, often through overseas distributors. Management blames "variability in the timing and periodic nature of customer orders and requested shipment dates," plus delivery problems and higher freight costs for some international customers because of the Russia–Ukraine war.
• Over-the-counter (OTC) sales rose 81% to $291,000. These are home-use tests sold through drugstores and online. The filing says the gain came mainly from sales to one new customer.
• Contract manufacturing was flat at $197,000 (+3%). This is work Biomerica does making or developing products for other companies.
• Physician's office sales were negligible at $2,000.

By region, Asia fell 30% to $467,000, North America rose 19% to $379,000, Europe slipped 7% to $284,000 and the Middle East rose 59% to $135,000. Biomerica depends heavily on a single customer in Asia: it made up 36% of sales this quarter, down from 48% a year ago. That one customer's ordering pattern drives a large share of every quarter's result. The quarter's decline is mostly that customer's region buying less.

Why the margin collapsed

Cost of sales rose 22% to $1.16 million while sales fell 8%, so cost of sales went from 69% of sales to 92%. The filing gives three reasons:

1. Higher contract manufacturing costs "associated with project activity and mix." Contract manufacturing revenue barely moved, but its costs went up.
2. Higher OTC product costs that came with the extra OTC sales and their product mix. The new OTC business appears to carry thin margins.
3. Higher "other direct costs reflecting production timing and inventory activity." These were partly offset by lower costs on clinical lab products, which sold fewer units.

The bigger structural issue is factory overhead. Biomerica makes its products in Irvine and in Mexicali, Mexico. Rent, salaried staff and equipment cost roughly the same whether the plants are busy or not. The fiscal 2026 annual report blamed "reduced absorption of fixed manufacturing costs" for its 8% margin. With sales falling again this quarter, the same thing applies: each unit sold has to carry more of those fixed costs.

Costs came down, partly for a one-off reason

Total operating expenses fell 14% to $1.33 million:

• Selling, general and administrative (SG&A) costs fell $206,000 (-15%) to $1.12 million. About $110,000 of that was lower outside professional fees. Last year's quarter included fees for filing the Employee Retention Credit (ERC) claim, a pandemic-era payroll tax refund, so this part of the saving is just a cost that didn't repeat. The rest came from lower payroll in administration and sales and marketing, and from lower credit-loss, stock-compensation and regulatory costs. Legal costs rose about $52,000.
• Research and development (R&D) was roughly flat at $206,000 (-3%). About $16,000 of staff cost moved out of R&D because employees spent more time on contract manufacturing projects. That was partly offset by inventory of hp+detect (the company's test for H. pylori, a stomach bacterium) used in R&D work.

The cost cuts were real but not large enough to offset the $321,000 drop in gross profit. As a result, the operating loss widened by $109,000.

What the headline numbers hide

Last year's profit was a tax refund, not the business. The year-ago quarter's "dividend, interest and other income" of $1.12 million was almost entirely a $1.1 million ERC benefit tied to an IRS refund received on July 21, 2025. Without it, last year's quarter would have shown a loss of roughly $1.10 million. Against that, this quarter's $1.23 million loss is about 12% worse. That is a fairer comparison than "from a $2,000 profit to a $1.23 million loss," but the direction is the same: the business is losing more money, not less.

Cash burn this quarter was flattered by slower bill-paying. Operations used $802,000 of cash, less than the $1.23 million net loss. About $192,000 of the gap is non-cash charges, mainly $134,000 of stock-based pay. Another $238,000 came from working capital. The largest item was a $216,000 rise in accounts payable and accrued expenses, meaning money owed to suppliers that hasn't been paid yet. Accrued pay owed to staff also rose $60,000. Before those timing effects, the business used about $1.04 million of cash in the quarter. The year-ago quarter's $268,000 burn looks low only because the $1.1 million refund came in as cash during it.

Receivables rose while sales fell. Gross receivables (money customers owe) rose 14% to $938,000 from $823,000 at May 31, even as quarterly sales were 8% lower than a year ago. The credit-loss provision for the quarter was small ($3,000, down from $38,000), so the company isn't signalling a collection problem. It's still worth watching for a company this dependent on a few customers. Inventory moved the right way, falling 4% to $1.63 million, and the quarter included a $24,000 release of reserves previously set aside for stock that might not sell.

Shareholder dilution is heavy, and most of it isn't in this quarter's EPS yet. On August 26 the company sold 1,393,705 new shares at $1.60 each to accredited investors in a private placement, raising $2.23 million gross and about $2.12 million after $111,000 of fees. The fees were still unpaid at quarter-end, so they will come out of cash later. Shares outstanding went from 3.20 million to 4.60 million, a 44% increase. Because the deal closed five days before quarter-end, the quarter's loss per share was spread over an average of just 3.30 million shares. From next quarter, the same dollar loss will be spread across about 4.6 million shares. That will make the loss per share look smaller without the business improving at all.

The $500,000 owed to the CEO. The balance sheet carries a $500,000 "secured promissory note payable – related party." It is the up-front payment from a group of buyers, including Biomerica's CEO, for the company's 6% stake in Diagnosis S.A., a Polish distributor. The note carries 8% interest and is due May 29, 2027. It is cancelled once Polish share-transfer procedures finish, which had not happened by August 31. If the transfer goes through, the $500,000 is effectively the sale price. If it doesn't, it's debt.

Going concern. The filing says plainly that current cash and cash equivalents "are insufficient to fund our operations and meet our obligations" for the twelve months after the statements were issued, and that this raises substantial doubt about the company's ability to continue as a going concern. Management says it is pursuing higher sales, lower expenses, sales of non-core assets, more debt or equity financing, and "other strategic alternatives." The board is evaluating "potential strategic opportunities, including partnerships and business combinations," which could include a merger or sale. The filing says there is no assurance any of this will happen.

Takeaway: Biomerica is spending money faster than its products bring it in. An 8% gross margin means the factory barely covers its own costs, and the sales decline is concentrated in its largest product line and largest customer. The August share sale bought roughly three quarters of runway at the current burn rate. The company needs Medicare-reimbursed inFoods tests and its new development contract to start showing up as meaningful revenue before that money runs out, or it will be selling more shares at low prices again.

Did last time's read hold up?

Our fiscal 2026 annual report flagged three things to watch, and one warning sign:

• The backlog warning was right. We noted that unshipped orders had fallen 54% to $604,000 at year-end, mostly bound for Asia, and that this didn't suggest a quick recovery in established products. Clinical lab sales fell 24% this quarter and Asia fell 30%.
• inFoods Medicare billing is moving, slowly. inFoods IBS is a blood test meant to identify foods that may trigger a patient's irritable bowel syndrome symptoms. Medicare pays $300 per test. As of October 15, 32 customer locations were set up to order inFoods under Medicare, up from 25 at August 31. Thirteen had placed Medicare orders, nine of them more than once. Monthly Medicare orders rose to 22 in September from 10 in August. Even at $300 each, 22 tests is about $6,600 of billing a month, and the filing notes that Biomerica's own revenue per test depends on its arrangement with the partner lab. It is progress, but not yet at a scale that shows up in the income statement.
• The new development contract hasn't shown up in revenue yet. The May 2026 master services agreement carries initial target fees of more than $1.75 million, earned as milestones are completed over 19 to 25 months. Management says the work is "progressing in accordance with the applicable Statements of Work." But contract manufacturing revenue was only $197,000, up 3%, and the costs tied to contract project activity rose.
• The funding call. We said the company would likely have to raise money again in fiscal 2027. The August placement (already known when the annual report was published) covered this quarter. The going-concern language and a new shelf registration (below) say more raising is likely.

What to watch next

• A bigger, but limited, fundraising capacity. On September 24 Biomerica filed a new shelf registration, a pre-approved filing that lets a company sell securities quickly when it chooses. It covers up to $250 million of stock, preferred stock, debt and warrants, and the SEC declared it effective on October 7. The $250 million figure is a ceiling on paper, not money in hand. The filing notes that SEC rules for small companies (General Instruction I.B.6 of Form S-3) cap how much it can actually sell each year based on the size of its publicly traded stock. A second registration, also effective October 7, lets the August placement investors resell their 1.39 million shares on the open market, which could weigh on the share price.
• Whether the gross margin recovers. For the margin to improve, the factories need more volume, mainly from a rebound in clinical lab orders or from development-contract milestones. If the margin stays near 8% for another quarter, cost cuts alone can't close the gap. SG&A is already down to $1.12 million a quarter.
• The Asian customer's next orders. With 36% of sales from one customer, one large order or a skipped one can move the quarter by double digits.
• Diagnosis S.A. share transfer. Completion would cancel the $500,000 note to the CEO and remove a related-party liability from the balance sheet.

Management gives no revenue or earnings guidance. Our read: the operating loss was $5.32 million in fiscal 2026 (about $1.3 million a quarter on average) and $1.23 million this quarter, and the gross margin has not recovered from the 8% level of fiscal 2026. Unless inFoods volumes and the development contract scale up within the next two to three quarters, Biomerica will need another share sale, or one of the "strategic alternatives" the filing mentions, before the end of fiscal 2027.